Bacteroides fragilis is an anaerobic bacterium naturally hosted in the human colon flora. B. fragilis D‐lactate dehydrogenase (BfD‐LDH) is an important enzyme which catalyzes the conversion of D‐lactate to pyruvate and regulates anaerobic glycolysis. In this study BfD‐LDH has been targeted for structure based drug design. B. fragilis D‐lactate dehydrogenase has been expressed, purified and inhibitory activities of 25 coumarin derivatives previously synthetize for their antioxidant activity were evaluated. Among the 25 coumarin derivatives, compound 6a, 5l, and 6b exhibited the highest inhibitory activity with IC50 values of 0,47 μM, 0,57 μM ve 0,057 μM, respectively. The results indicate that the mechanism by which 6a, 5l and 6b coumarin derivatives inhibit BfD‐LDH by reversible non-competitive inhibition. Docking experiments were carried out to further explain the results and compare the theoretical and experimental affinity of these compounds to the BfD‐LDH protein. According to docking results, all coumarins bind to the site occupied by pyruvate and the nicotinamide ring of NADH.
Inhibitory effects of arylcoumarin derivatives on Bacteroides fragilis D-lactate dehydrogenase
Posted by
Ozal Mutlu
on 12 09 2019
Related content
12 05 2022
< 1 minute
Coupling stabilizers open KV1-type potassium channels
ABSTRACT: The opening and closing of voltage-gated ion channels are regulated by voltage sensors...
12 11 2021
< 1 minute
Responding to the Challenge Posed by the Generic Control of Substances
Drug monitoring organizations report that new psychoactive substances continue to emerge, posing...
12 10 2021
< 1 minute
Boost analytical experiments with phys-chem properties
Physicochemical properties have a fundamental impact on analytical experiment conditions,...
12 09 2021
< 1 minute
Efficient acetaminophen removal from water and hospital effluents treatment by activated carbons derived from Brazil nutshells
Abstract Activated carbons from Brazil nutshells were produced by ZnCl2-activation at different...